Skip to main content
Erschienen in: Tumor Biology 12/2016

08.08.2015 | Original Article

RETRACTED ARTICLE: Regulation of activating protein-4-associated metastases of non-small cell lung cancer cells by miR-144

verfasst von: Feng Gao, Tao Wang, Zefeng Zhang, Rui Wang, Yang Guo, Junfeng Liu

Erschienen in: Tumor Biology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Activating protein-4 (AP4) has been recently shown to regulate the cancer metastases in some cancers including non-small cell lung cancer (NSCLC). Specifically, AP4 regulates mTor/p21 and transforming growth factor β (TGFβ) receptor signaling pathway to increase an epithelial-mesenchymal transition process to augment cell invasiveness. Nevertheless, how AP4 is regulated in NSCLC has not been studied. Here, we showed that in the specimens from the NSCLC patients, the levels of miR-144 were significantly decreased and the levels of AP4 were significantly increased, compared to the paired non-tumor lung tissue. The levels of miR-144 and AP4 inversely correlated in patients’ specimens. Bioinformatics analyses revealed that miR-144 targeted the 3′-UTR of AP4 mRNA to inhibit its translation, confirmed by luciferase-reporter assay. Moreover, miR-144 overexpression inhibited AP4-mediated cell invasiveness, while miR-144 depletion increased AP4-mediated cell invasiveness in NSCLC cells. Together, our data suggest that miR-144 suppression may be the cause of the increased levels of AP4, as well as the augmented cancer metastases, in NSCLC.
Literatur
1.
Zurück zum Zitat Mitsudomi T, Suda K, Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10:235–44.CrossRefPubMed Mitsudomi T, Suda K, Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10:235–44.CrossRefPubMed
2.
Zurück zum Zitat Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer. 2013;80:120–30.CrossRefPubMed Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer. 2013;80:120–30.CrossRefPubMed
3.
Zurück zum Zitat Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5:S389–96.PubMedPubMedCentral Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5:S389–96.PubMedPubMedCentral
4.
Zurück zum Zitat Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits growth of non-small cell lung cancer in vitro and in vivo. Cell Signal. 2015;27:1208–13.CrossRefPubMed Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits growth of non-small cell lung cancer in vitro and in vivo. Cell Signal. 2015;27:1208–13.CrossRefPubMed
5.
Zurück zum Zitat Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits mmp9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014;35:11051–6.CrossRefPubMed Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits mmp9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014;35:11051–6.CrossRefPubMed
6.
Zurück zum Zitat Liu G, Xu S, Jiao F, Ren T, Li Q. Vascular endothelial growth factor b coordinates metastasis of non-small cell lung cancer. Tumour Biol. 2015;36:2185–91.CrossRefPubMed Liu G, Xu S, Jiao F, Ren T, Li Q. Vascular endothelial growth factor b coordinates metastasis of non-small cell lung cancer. Tumour Biol. 2015;36:2185–91.CrossRefPubMed
7.
Zurück zum Zitat Lv Q, Shen R, Wang J. RBPJ inhibition impairs the growth of lung cancer. Tumour Biol. 2015;36:3751–6.CrossRefPubMed Lv Q, Shen R, Wang J. RBPJ inhibition impairs the growth of lung cancer. Tumour Biol. 2015;36:3751–6.CrossRefPubMed
8.
Zurück zum Zitat Pei J, Lou Y, Zhong R, Han B. MMP9 activation triggered by epidermal growth factor induced foxo1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 2014;35:6673–8.CrossRefPubMed Pei J, Lou Y, Zhong R, Han B. MMP9 activation triggered by epidermal growth factor induced foxo1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 2014;35:6673–8.CrossRefPubMed
9.
Zurück zum Zitat Zhao D, Lu Y, Yang C, Zhou X, Xu Z. Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer. Tumour Biol. 2015;36:3637–42.CrossRefPubMed Zhao D, Lu Y, Yang C, Zhou X, Xu Z. Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer. Tumour Biol. 2015;36:3637–42.CrossRefPubMed
10.
Zurück zum Zitat Bernardini N, Giannessi F, Bianchi F, Dolfi A, Lupetti M, Citti L, et al. Involvement of basic fibroblast growth factor in suramin-induced inhibition of v79/AP4 fibroblast cell proliferation. Br J Cancer. 1993;67:1209–16.CrossRefPubMedPubMedCentral Bernardini N, Giannessi F, Bianchi F, Dolfi A, Lupetti M, Citti L, et al. Involvement of basic fibroblast growth factor in suramin-induced inhibition of v79/AP4 fibroblast cell proliferation. Br J Cancer. 1993;67:1209–16.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H. P53-induced mir-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 2014;74:532–42.CrossRefPubMed Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H. P53-induced mir-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 2014;74:532–42.CrossRefPubMed
12.
Zurück zum Zitat Jackstadt R, Jung P, Hermeking H. AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation. Cell Death Dis. 2013;4:e775.CrossRefPubMedPubMedCentral Jackstadt R, Jung P, Hermeking H. AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation. Cell Death Dis. 2013;4:e775.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Jackstadt R, Roh S, Neumann J, Jung P, Hoffmann R, Horst D, et al. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med. 2013;210:1331–50.CrossRefPubMedPubMedCentral Jackstadt R, Roh S, Neumann J, Jung P, Hoffmann R, Horst D, et al. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med. 2013;210:1331–50.CrossRefPubMedPubMedCentral
15.
16.
Zurück zum Zitat Goc A, Al-Azayzih A, Abdalla M, Al-Husein B, Kavuri S, Lee J, et al. P21 activated kinase-1 (pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor beta expression and enhanced matrix metalloproteinase 9 secretion. J Biol Chem. 2013;288:3025–35.CrossRefPubMed Goc A, Al-Azayzih A, Abdalla M, Al-Husein B, Kavuri S, Lee J, et al. P21 activated kinase-1 (pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor beta expression and enhanced matrix metalloproteinase 9 secretion. J Biol Chem. 2013;288:3025–35.CrossRefPubMed
17.
Zurück zum Zitat Chiang YA, Shao W, Xu XX, Chernoff J, Jin T. P21-activated protein kinase 1 (pak1) mediates the cross talk between insulin and beta-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male c57bl/6 mice. Endocrinology. 2013;154:77–88.CrossRefPubMed Chiang YA, Shao W, Xu XX, Chernoff J, Jin T. P21-activated protein kinase 1 (pak1) mediates the cross talk between insulin and beta-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male c57bl/6 mice. Endocrinology. 2013;154:77–88.CrossRefPubMed
18.
Zurück zum Zitat Gong H, Han S, Yao H, Zhao H, Wang Y. AP4 predicts poor prognosis in nonsmall cell lung cancer. Mol Med Rep. 2014;10:336–40.PubMed Gong H, Han S, Yao H, Zhao H, Wang Y. AP4 predicts poor prognosis in nonsmall cell lung cancer. Mol Med Rep. 2014;10:336–40.PubMed
19.
Zurück zum Zitat Wang W, Wu X, Tian Y. Crosstalk of AP4 and TGFbeta receptor signaling in NSCLC. Tumour Biol. 2015;36:447–52.CrossRefPubMed Wang W, Wu X, Tian Y. Crosstalk of AP4 and TGFbeta receptor signaling in NSCLC. Tumour Biol. 2015;36:447–52.CrossRefPubMed
20.
Zurück zum Zitat Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through mir-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentral Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through mir-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J, et al. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through mir-148a. Cell Physiol Biochem. 2015;36:1186–96.CrossRefPubMed Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J, et al. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through mir-148a. Cell Physiol Biochem. 2015;36:1186–96.CrossRefPubMed
22.
Zurück zum Zitat Ji D, Li B, Shao Q, Li F, Li Z, Chen G. MiR-22 suppresses BMP7 in the development of cirrhosis. Cell Physiol Biochem. 2015;36:1026–36.CrossRefPubMed Ji D, Li B, Shao Q, Li F, Li Z, Chen G. MiR-22 suppresses BMP7 in the development of cirrhosis. Cell Physiol Biochem. 2015;36:1026–36.CrossRefPubMed
23.
Zurück zum Zitat Song W, Li Q, Wang L, Wang L. Modulation of foxo1 expression by mir-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 2015;35:184–90.CrossRefPubMed Song W, Li Q, Wang L, Wang L. Modulation of foxo1 expression by mir-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 2015;35:184–90.CrossRefPubMed
24.
Zurück zum Zitat Wang Q, Cai J, Wang J, Xiong C, Zhao J. Mir-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 2014;35:12743–8.CrossRefPubMed Wang Q, Cai J, Wang J, Xiong C, Zhao J. Mir-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 2014;35:12743–8.CrossRefPubMed
26.
Zurück zum Zitat Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed
27.
Zurück zum Zitat Cao T, Li H, Hu Y, Ma D, Cai X. Mir-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting e2f3. Tumour Biol. 2014;35:10759–64.CrossRefPubMed Cao T, Li H, Hu Y, Ma D, Cai X. Mir-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting e2f3. Tumour Biol. 2014;35:10759–64.CrossRefPubMed
28.
Zurück zum Zitat Guan H, Liang W, Xie Z, Li H, Liu J, Liu L, et al. Down-regulation of mir-144 promotes thyroid cancer cell invasion by targeting zeb1 and zeb2. Endocrine. 2015;48:566–74.CrossRefPubMed Guan H, Liang W, Xie Z, Li H, Liu J, Liu L, et al. Down-regulation of mir-144 promotes thyroid cancer cell invasion by targeting zeb1 and zeb2. Endocrine. 2015;48:566–74.CrossRefPubMed
29.
Zurück zum Zitat Guo Y, Ying L, Tian Y, Yang P, Zhu Y, Wang Z, et al. Mir-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J. 2013;280:4531–8.CrossRefPubMed Guo Y, Ying L, Tian Y, Yang P, Zhu Y, Wang Z, et al. Mir-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J. 2013;280:4531–8.CrossRefPubMed
30.
Zurück zum Zitat Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, et al. Downregulation of mir-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis. 2012;33:2391–7.CrossRefPubMed Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, Tanaka F, et al. Downregulation of mir-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis. 2012;33:2391–7.CrossRefPubMed
31.
Zurück zum Zitat Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, et al. Clinical significance of mir-144-zfx axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer. 2012;107:1345–53.CrossRefPubMedPubMedCentral Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, et al. Clinical significance of mir-144-zfx axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer. 2012;107:1345–53.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, Pallone F, et al. Differential expression of mir-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46:1391–402.CrossRefPubMed Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, Pallone F, et al. Differential expression of mir-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46:1391–402.CrossRefPubMed
33.
Zurück zum Zitat Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417–23.CrossRefPubMed Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417–23.CrossRefPubMed
34.
Zurück zum Zitat Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed
Metadaten
Titel
RETRACTED ARTICLE: Regulation of activating protein-4-associated metastases of non-small cell lung cancer cells by miR-144
verfasst von
Feng Gao
Tao Wang
Zefeng Zhang
Rui Wang
Yang Guo
Junfeng Liu
Publikationsdatum
08.08.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3866-4

Weitere Artikel der Ausgabe 12/2016

Tumor Biology 12/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.